SLC19A3 gene encephalopathy, also known as thiamine metabolism dysfunction syndrome 2 (THMD2), is a rare genetic condition characterized by a range of neurological symptoms. This condition is caused by mutations in the SLC19A3 gene, which plays a crucial role in thiamine (vitamin B1) transport within the body. Thiamine is essential for energy production and normal neuronal function. When its transport is impaired due to mutations in the SLC19A3 gene, it can lead to a spectrum of neurological manifestations including seizures, developmental delay, and in severe cases, encephalopathy.
Recognizing and diagnosing SLC19A3 gene encephalopathy early is critical, as it is a condition that can respond to high doses of thiamine and biotin, potentially improving neurological outcomes. To facilitate this, genetic testing is available and is a key tool in the diagnostic process. The test specifically looks for mutations in the SLC19A3 gene that are known to cause the disorder.
In the UAE, DNA Labs offers a comprehensive genetic test for diagnosing SLC19A3 gene encephalopathy. The test is meticulously designed to identify the genetic mutations associated with this condition, providing essential information for an accurate diagnosis. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the significant impact it can have on patient care. Conducted in a state-of-the-art facility, DNA Labs UAE ensures high-quality testing standards, providing patients and healthcare providers with reliable and actionable genetic insights that can guide treatment decisions and improve patient outcomes.
The "TRAF3 Gene Encephalopathy Acute Infection-Induced Herpes-Specific Susceptibility to Type 5 Genetic Test" is a specialized diagnostic assessment available at DNA Labs UAE. This test is designed to identify individuals who have a genetic predisposition to developing encephalopathy, a serious and potentially life-threatening brain inflammation, following acute infection with type 5 herpes simplex virus. This condition is attributed to specific mutations in the TRAF3 gene, which plays a critical role in the immune system's response to viral infections.
Understanding one's genetic susceptibility to this condition is crucial for implementing preventative measures and tailoring treatment strategies in the event of an infection. The test is particularly recommended for individuals with a family history of herpes-induced encephalopathy or unexplained cases of encephalitis following viral infections.
The test is priced at 4400 AED and is conducted at DNA Labs UAE, a facility known for its advanced genetic testing capabilities and commitment to providing accurate and comprehensive diagnostic services. This test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed for the presence of mutations in the TRAF3 gene that are associated with an increased risk of herpes-specific encephalopathy. Results from this test can provide invaluable information for affected individuals and their families, guiding healthcare decisions and interventions.
RANBP2 Gene Encephalopathy Acute Necrotizing Type 1 is a rare genetic disorder characterized by severe neurological symptoms, including encephalopathy, which is a brain disease that leads to decreased brain function. This condition is linked to mutations in the RANBP2 gene. The genetic test for this condition is crucial for accurate diagnosis, allowing for appropriate management and treatment of the affected individuals.
At DNA Labs UAE, the genetic test for RANBP2 Gene Encephalopathy Acute Necrotizing Type 1 is available. This test involves analyzing the patient's DNA to detect mutations in the RANBP2 gene that are associated with the disease. The process is comprehensive and ensures a reliable diagnosis, which is essential for guiding treatment decisions and providing prognostic information.
The cost of the test is 4400 AED. This investment covers the entire testing process, from sample collection to detailed genetic analysis and reporting. By choosing DNA Labs UAE for this test, patients and healthcare providers can expect accurate and timely results, which are critical for managing this severe genetic disorder effectively.
The SERPINI1 gene encephalopathy, also known as familial encephalopathy with neuroserpin inclusion bodies (FENIB), is a rare genetic disorder characterized by the accumulation of mutant neuroserpin protein within the brain's neurons. This accumulation leads to neuronal damage, resulting in a range of neurological symptoms such as dementia, epilepsy, and movement disorders. The condition is inherited in an autosomal dominant manner, meaning a single copy of the mutated gene can cause the disorder.
Genetic testing for SERPINI1 gene encephalopathy is a crucial step in diagnosing this condition, enabling healthcare professionals to confirm the presence of mutations in the SERPINI1 gene that are responsible for the disease. This test involves analyzing the DNA to identify mutations in the SERPINI1 gene that lead to the abnormal production of neuroserpin.
At DNA Labs UAE, the genetic test for SERPINI1 gene encephalopathy is available, providing a vital diagnostic tool for families affected by this condition. The test cost is 4400 AED, which reflects the comprehensive analysis and the specialized expertise required to interpret the results accurately. Through this test, affected individuals and their families can gain a better understanding of their condition, enabling informed decisions regarding management and treatment options. Additionally, it can help in identifying at-risk family members who may benefit from genetic counseling and potential early intervention strategies.
The BSCL2 gene enccephalopathy progressive with or without lipodystrophy genetic test is a specialized diagnostic tool offered by DNA Labs UAE. This test is specifically designed to detect mutations in the BSCL2 gene, which are known to cause a rare and progressive encephalopathy, often associated with lipodystrophy - a condition characterized by the abnormal distribution of fat in the body. The BSCL2 gene plays a crucial role in the development and function of the nervous system and adipose tissue. Mutations in this gene can lead to severe neurological impairment and metabolic abnormalities.
The test is conducted through a comprehensive analysis of the patient's DNA to identify any genetic anomalies present in the BSCL2 gene. It is a critical tool for clinicians in diagnosing this condition, enabling them to provide targeted treatment and management strategies for affected individuals. Early diagnosis through genetic testing can significantly improve the quality of life for patients by addressing symptoms and preventing progression where possible.
The cost of the BSCL2 gene encephalopathy progressive with or without lipodystrophy genetic test at DNA Labs UAE is set at 4400 AED. This cost includes the full processing of the patient's genetic material, analysis by expert geneticists, and a detailed report of the findings. Patients and healthcare providers considering this test should consult with a genetic counselor or specialist to understand its implications fully and how its results may influence medical management and family planning decisions.
The COLQ gene is crucial for the proper functioning of the neuromuscular junction, where nerve cells meet muscle cells to facilitate muscle contraction. Mutations in the COLQ gene can lead to a condition known as endplate acetylcholinesterase deficiency. This genetic disorder disrupts the breakdown of the neurotransmitter acetylcholine, leading to prolonged muscle contraction and resulting in symptoms such as muscle weakness and fatigue.
To diagnose this condition, a genetic test targeting the COLQ gene can be conducted. This test is available at DNA Labs UAE, a reputable facility known for its advanced genetic testing services. The test specifically looks for mutations in the COLQ gene that are known to cause endplate acetylcholinesterase deficiency. Identifying these mutations can help in confirming the diagnosis, understanding the disease progression, and planning appropriate management strategies for affected individuals.
The cost of the COLQ Gene Endplate Acetylcholinesterase Deficiency Genetic Test at DNA Labs UAE is 4400 AED. This price includes the cost of sample collection, genetic analysis, and a comprehensive report of the findings. Patients considering this test should consult with their healthcare provider to discuss its relevance and implications based on their symptoms and medical history.
The PLEC Gene Epidermolysis Bullosa Simplex with Muscular Dystrophy Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, aimed at identifying mutations in the PLEC gene. These mutations are known to cause Epidermolysis Bullosa Simplex with Muscular Dystrophy (EBS-MD), a rare genetic disorder that affects the skin and muscles, leading to symptoms such as blistering of the skin and progressive muscle weakness. The test is crucial for early diagnosis, enabling targeted interventions and management strategies to improve the quality of life for affected individuals. The cost of the test is set at 4400 AED, reflecting the intricate technology and expertise involved in conducting this advanced genetic analysis. This test represents a significant step forward in the personalized medicine approach, offering hope to families affected by this challenging condition.
The PCDH19 gene is associated with early infantile epileptic encephalopathy type 9 (EIEE9), a rare genetic disorder primarily affecting females. It is characterized by the onset of seizures in infancy or early childhood, which can be accompanied by developmental delays and cognitive impairments as the condition progresses. The PCDH19 gene plays a crucial role in the development and function of the nervous system, and mutations in this gene are directly linked to the symptoms of EIEE9.
Genetic testing for mutations in the PCDH19 gene is essential for the accurate diagnosis of EIEE9. This testing helps in understanding the genetic basis of the condition, which can guide treatment decisions and provide information on the risk of recurrence in future pregnancies. DNA Labs UAE offers a comprehensive genetic test targeting the PCDH19 gene, providing a reliable diagnosis for families affected by early infantile epileptic encephalopathy type 9.
The cost of the PCDH19 gene test at DNA Labs UAE is 4400 AED. This specialized test is conducted using advanced genetic sequencing technologies to identify mutations in the PCDH19 gene that are responsible for EIEE9. By choosing DNA Labs UAE for this genetic testing, patients and their families can expect accurate results, which are crucial for the management and understanding of this challenging condition.
The EMD gene test for Emery-Dreifuss muscular dystrophy type 1 is a specialized genetic test conducted to diagnose Emery-Dreifuss muscular dystrophy (EDMD) type 1, a condition characterized by muscle weakness and wasting, joint contractures, and heart problems. This test specifically looks for mutations in the EMD gene, which provides instructions for producing emerin, a protein essential for the structural integrity and function of muscle cells and heart cells. Mutations in the EMD gene disrupt the normal production or function of emerin, leading to the symptoms associated with EDMD type 1.
DNA Labs UAE offers this genetic test at a cost of 4400 AED. The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to identify any mutations in the EMD gene. It is a critical tool for confirming the diagnosis of EDMD type 1, enabling appropriate management and treatment plans for affected individuals. Additionally, this test can be used for carrier testing and prenatal diagnosis, providing valuable information for family planning decisions.
The LMNA Gene Emery-Dreifuss Muscular Dystrophy Type 2 Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the LMNA gene, which are associated with Emery-Dreifuss Muscular Dystrophy Type 2 (EDMD2). EDMD2 is a rare genetic condition characterized by muscle weakness and wasting, joint contractures, and heart problems, often leading to significant physical disability and cardiac issues. This test plays a critical role in the early detection and management of the disease, enabling healthcare providers to tailor treatments and interventions more effectively.
Priced at 4400 AED, the test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the lab for specific genetic mutations in the LMNA gene. Positive identification of these mutations can confirm a diagnosis of EDMD2, allowing for early and more precise medical and therapeutic interventions. Given the complexity of the disease and the importance of early diagnosis in managing symptoms and improving quality of life, the LMNA Gene Emery-Dreifuss Muscular Dystrophy Type 2 Genetic Test is a valuable resource for individuals exhibiting symptoms of the disease or those with a family history of EDMD2.
